Targets › EBV
2 programs from 2 companies in 3 trials: 2 Phase 1, 1 Phase 3; Infectious disease, Oncology; next expected readout Jun 2027.
Open in Phaseline: the race on EBV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tobias Feuchtinger | Multivirus (CMV, EBV, AdV)-specific T cells Adoptive transfer of multivirus-specific T cells targeting CMV, EBV, and AdV | CMV, EBV, ADV | Phase 3 | AdV Infection | Mar 2028 |
| Daihong Liu | EBV-AST Cell Injection Epstein-Barr virus antigen-specific cytotoxic T-lymphocyte product generated by ex vivo st | EBV | Phase 1 | Epstein-Barr Virus-Associated Lymphoproliferative Disorders; EBV-DNA Viremia | Jun 2027 |
Epstein-Barr Virus-Associated Lymphoproliferative Disorders (1) EBV-DNA Viremia (1) AdV Infection (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.